Individualizing Treatment for Asthma in Primary Care (Full Study)
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- DARTNet Institute
- Study ID
- NCT07052942
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Asthma
- Asthma Attack
- Asthma Exacerbations
Eligibility Criteria
- Sex
- ALL
- Age
- 13 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Inhaled corticosteroid (ICS) — DRUGParticipants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy.
- Azithromycin — DRUGParticipants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects.
- Asthma Symptom Monitoring Web-based Application — OTHERAll participants will be provided access to the Asthma Symptom Monitoring (ASM) tools. ASM can be integrated with electronic health records (EHR) or used as a stand alone application. Participants will answer 5 questions about their asthma each week. If symptoms are problematic, participants can request a call back from a person on their care team. Participants can view a graph of their data, watch videos, and record peak flows. Clinicians and members of the care team can view data in the EHR (not for stand alone web app).
Study Details
While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects. This study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced "Ricks," and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.
Key Dates
- Start date
- Aug 1, 2025
- Status verified
- Oct 2025
- Primary completion
- Nov 15, 2029
- Completion
- Nov 15, 2029
Study Design
- Enrollment
- 3,200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Inhaled corticosteroids as part of rescue therapy (R-ICS)Maintenance And Reliever Therapy (MART), or Patient Activated Reliever Triggered Inhaled Corticosteroids (PARTICS) - this includes budesonide-albuterol (AirSupra)
- Active Comparator: Azithromycin (AZ)Azithromycin - 500mg three times per week. Can be reduced to 250 mg three times per week for side effects.
- Other: Enhanced Usual CareParticipants will be asked to use an online Asthma Symptom Monitoring (ASM) tool to enhance communication with the medical team as well as self-awareness of their asthma symptoms. There are no "study drugs" in this intervention.
- Active Comparator: Inhaled corticosteroids as part of rescue therapy (R-ICS) + AzithromycinR-ICS either as MART therapy or PARTICS + Azithromycin
Primary Outcome Measure
Rate of Asthma Exacerbations Per Year [ Time Frame: Follow-up is up to 16 months. ]
Central Contacts
- Brian K Manning, MPH1-866-297-8521
- Joel Shields, MA1-866-297-8521
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| DARTNet Institute | Aurora | Colorado | 80045 | |
| University Colorado-Denver | Aurora | Colorado | 80045 | |
| AdventHealth | Orlando | Florida | 32803 | - |
| University of Kansas | Kansas City | Kansas | 66160 | - |
| Reliant Medical Group | Worcester | Massachusetts | 01608 | Richard Rosiello, MD 508-595-2105 Larry Garber, MD 508-425-6132 |
| University of Missouri | Columbia | Missouri | 65211 | |
| Rutgers Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | |
| Mt. Sinai School of Medicine | New York | New York | 10029 | |
| University North Carolina | Chapel Hill | North Carolina | 27599 | |
| Atrium Health | Charlotte | North Carolina | 28207 | |
| JPS Health Network | Fort Worth | Texas | 76104 | - |
| Kelsey Research Foundation | Houston | Texas | 77005 | |
| University of Washington | Seattle | Washington | 98105 | - |
Find similar trials in Aurora, CO
Related Studies
- Personalized Environment and Genes StudyRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
- Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway InflammationPHASE1 · Recruiting · Benjamin Medoff · Boston, Massachusetts
- Study of the Effect of Innate on the Inflammatory Response to EndotoxinRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina
- NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina